Cocrystal Pharma Inc Quick Ratio (COCP) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Cocrystal Pharma Inc   (NASDAQ: COCP)

Cocrystal Pharma Inc 's Quick Ratio

COCP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.83 below Cocrystal Pharma Inc average.

Within Major Pharmaceutical Preparations industry 368 other companies have achieved higher Quick Ratio than Cocrystal Pharma Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1032 to 2141.

Explain Quick Ratio?
How much Cash & cash equivalents COCP´s has?
What are COCP´s Current Liabilities?




COCP Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 72.79 % 16.28 % -11.8 % -27.85 % -37 %
Y / Y Cash & cash equivalent Change -54.49 % -32.31 % -28.75 % -40.64 % -73.73 %
Quick Ratio MRQ 0.83 2.48 3.74 6.47 3.15
COCP's Total Ranking # 2141 # 1032 # 726 # 428 # 686
Seq. Current Liabilities Change 38.71 % 0.53 % 57.12 % -21.14 % -6.66 %
Seq. Cash & cash equivalent Change -53.7 % -33.31 % -9.11 % 62.17 % -31.14 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 369
Healthcare Sector # 664
Overall Market # 2141


Quick Ratio Statistics
High Average Low
62 8.48 0.01
(Sep 30 2021)   (Mar 31 2012)




Financial Statements
Cocrystal Pharma Inc 's Current Liabilities $ 3 Millions Visit COCP's Balance sheet
Cocrystal Pharma Inc 's Cash & cash equivalent $ 2 Millions Visit COCP's Balance sheet
Source of COCP's Sales Visit COCP's Sales by Geography


Cumulative Cocrystal Pharma Inc 's Quick Ratio

COCP's Quick Ratio for the trailling 12 Months

COCP Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 9.45 % -17.13 % -25.44 % -29.96 % -27.51 %
Y / Y Cash & cash equivalent TTM Growth -37.49 % -49.51 % -57.94 % -63.11 % -64.05 %
Quick Ratio TTM 2.85 3.74 4.26 4.53 5
Total Ranking TTM # 3768 # 3683 # 2822 # 3115 # 2670
Seq. Current Liabilities TTM Growth 17.03 % 4.25 % -3.89 % -6.66 % -11.39 %
Seq. Cash & cash equivalent TTM Growth -10.73 % -8.46 % -9.68 % -15.31 % -27.9 %


On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $2.62 millions, cumulative Quick Ratio decreased to 2.85 below the Cocrystal Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Cocrystal Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3683 to 3768.

Explain Quick Ratio?
How much Cash & cash equivalents COCP´s has?
What are COCP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 431
Healthcare Sector # 876
Within the Market # 3768


trailing twelve months Quick Ratio Statistics
High Average Low
36.13 7.37 0.02
(Mar 31 2022)  




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Madrigal Pharmaceuticals Inc   2.24 $ 839.419  Millions$ 374.204  Millions
Rockwell Medical inc   2.23 $ 24.936  Millions$ 11.174  Millions
Ars Pharmaceuticals Inc   2.22 $ 143.845  Millions$ 64.728  Millions
Alnylam Pharmaceuticals Inc   2.19 $ 3,308.147  Millions$ 1,512.513  Millions
Xeris Biopharma Holdings Inc   2.16 $ 243.494  Millions$ 112.826  Millions
Ardelyx inc   2.13 $ 281.830  Millions$ 132.220  Millions
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions

Date modified: 2026-09-26T07:21:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.